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Abstract
Background: Testicular microliths are calcifications found within the seminiferous tubules. In
humans, testicular microlithiasis (TM) has an unknown etiology but may be significantly associated
with testicular germ cell tumors. Factors inducing microlith development may also, therefore, act
as susceptibility factors for malignant testicular conditions. Studies to identify the mechanisms of
microlith development have been hampered by the lack of suitable animal models for TM.
Methods: This was an observational study of the testicular phenotype of different mouse models.
The mouse models were: cryptorchid mice, mice lacking androgen receptors (ARs) on the Sertoli
cells (SCARKO), mice with a ubiquitous loss of androgen ARs (ARKO), hypogonadal (hpg) mice
which lack circulating gonadotrophins, and hpg mice crossed with SCARKO (hpg.SCARKO) and
ARKO (hpg.ARKO) mice.
Results: Microscopic TM was seen in 94% of hpg.ARKO mice (n = 16) and the mean number of
microliths per testis was 81 +/- 54. Occasional small microliths were seen in 36% (n = 11) of hpg
testes (mean 2 +/- 0.5 per testis) and 30% (n = 10) of hpg.SCARKO testes (mean 8 +/- 6 per testis).
No microliths were seen in cryptorchid, ARKO or SCARKO mice. There was no significant effect
of FSH or androgen on TM in hpg.ARKO mice.
Conclusion: We have identified a mouse model of TM and show that lack of endocrine stimulation
is a cause of TM. Importantly, this model will provide a means with which to identify the
mechanisms of TM development and the underlying changes in protein and gene expression.
Background
Testicular microlithiasis (TM) is characterised by the pres-
ence of microcalcification within the seminiferous
tubules. In the normal human population the incidence is
between 1.5 and 5.6% [1-3] and in itself microlithiasis is
benign but there may be significant association with
malignant conditions such as testicular germ cell tumors
(TGCT) [4-7] and other conditions such as cryp-
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torchidism, varicocele, infertility, and testicular torsion
[8,9]. In addition, it has been suggested that there may be
a genetic predisposition to TM which is linked to TGCT
formation so that identifying the underlying causes of
microlithiasis may help identify susceptibility factors for
TGCTs [5]. Development of an animal model of TM
would, therefore, not only represent significant progress
towards an understanding of the origins and underlying
molecular mechanisms of microlithiasis but may help
identify associated risk factors for other conditions.
The hypogonadal (hpg) mouse lacks gonadotrophin-
releasing hormone (GnRH) and circulating levels of
luteinising hormone (LH) and follicle-stimulating hor-
mone (FSH) are undetectable [10]. As part of an ongoing
study of the endocrine regulation of spermatogenesis we
have crossed these hpg mice with mice lacking androgen
receptors (AR) either ubiquitously (ARKO mice) or specif-
ically in the Sertoli cells (SCARKO mice). In this report we
describe the unexpected and consistent occurrence of
microlithiasis in hpg.ARKO mice.
Methods
Animals and treatments
All mice were bred and all procedures carried out under
UK Home Office Licence and with the approval of a local
ethical review committee. SCARKO and ARKO mice have
been previously generated by crossing female mice carry-
ing an Ar  with a floxed exon 2 (Arfl) with male mice
expressing Cre under the regulation of the Sertoli cell spe-
cific promoter of AMH or the ubiquitous promoter PGK-
1 [11,12]. In order to produce hpg.SCARKO mice, hpg
mice (C3HE/HeH-101/H) were initially crossed with
mice carrying the Arfl allele (Swiss-Webster/129) and with
mice expressing AMH-Cre (C57-BL6/SJL). From these
crosses, female mice heterozygous for the GnRH deletion
(hpg/+) and homozygous for the Arfl allele were crossed
with  hpg/+ AMH-Cre males (heterozygous or
homozygous for the Cre transgene) to generate
hpg.SCARKO mice. The hpg deletion and Arfl allele were
detected by PCR analysis of ear lysates and confirmed at
termination by the presence of the shorter Ar allele in a
testis extract [12,13]. The generation of hpg.ARKO mice
was similar except that PGK-Cre (C57-BL6/SJL) replaced
AMH-Cre. The hpg.ARKO males were detected by PCR of
ear lysates for Sry and deletion of GnRH and confirmed at
termination by the absence of epididymides, seminal ves-
icles and ductus deferens. Cryptorchidism was induced in
normal 20-day old mice (C3H/HeH-101/H) as described
previously [14].
To determine the effects of hormone treatment, adult hpg,
hpg.SCARKO and hpg.ARKO mice (10 weeks of age) were
injected sub-cutaneously with 8 IU recombinant human
FSH (rhFSH) (Serono Ltd, London, UK) in 0.2 ml PBS
(phosphate buffered saline, pH 7.4, Sigma Aldrich, Poole,
UK) once daily or had silastic tubing (2 cm) containing
either testosterone (T) or dihydrotestosterone (DHT)
implanted subcutaneously. Treatments lasted for 7 days.
Adult mice were euthanized at 911 weeks of age by cervi-
cal dislocation and the testes were fixed overnight in
Bouin's solution.
Histology and microlith numbers
Testes were embedded in Technovit 7100 resin, cut into
sections (20 μm), and stained with Harris' hematoxylin.
Microliths were counted in every 6th section to generate an
estimate of numbers per testis.
Statistical analysis
Data were analysed using single factor analysis of variance
followed by Fisher's test for multiple comparisons. All
data are expressed as mean ± SEM.
Results
Microscopic analysis of hpg.ARKO mice showed that in
94% (n = 16) of these animals non-cellular structures,
closely resembling the morphology of human testicular
microliths [15], were present within the seminiferous
tubules (Fig 1). In section the microliths had a round/oval
appearance with a maximum diameter of about 45 μm
(Fig 1). Most microliths were present singly but in some
sections 2 or 3 microliths were present within the same
tubule section. Some microliths were closely apposed to
Sertoli cells while others had only occasional close cellu-
lar associations (Fig 1B&1C).
Examination of hpg and hpg.SCARKO mice showed that
occasional, small microliths were present in 36% (n = 11)
of hpg testes and 30% (n = 10) of hpg.SCARKO testes (Fig
1D). We did not observe any evidence of the presence of
microliths in ARKO mice (n = 4) or in SCARKO mice (n =
7) or in normal cryptorchid mice (n = 4).
The mean number of microliths/testis in hpg.ARKO mice
was 81 ± 54 while in hpg and hpg.SCARKO mice there were
2 ± 0.5 and 8 ± 6 microliths per testis respectively. Treat-
ment of hpg, hpg.SCARKO or hpg.ARKO mice with FSH did
not alter the number of microliths. Treatment of mice
with androgen increased the average number of micro-
liths per testis in hpg.ARKO mice but this was not signifi-
cant (incidence after T = 234 ± 75, incidence after DHT =
241 ± 75).
Discussion
The generation of an animal model of TM represents sig-
nificant progress towards understanding this condition. It
is unlikely that the cause of TM in the hpg.ARKO mouse is
identical to that in most human cases of TM since TMReproductive Biology and Endocrinology 2009, 7:88 http://www.rbej.com/content/7/1/88
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arises in individuals with normal endocrinology
although, interestingly, TM has been shown to be diag-
nostic of McCune-Albright Syndrome [16] in which testic-
ular symptoms appear to arise most commonly from
precocious activation of the Sertoli cells [17]. Irrespective
of the cause, importantly we have identified conditions in
which there is consistent development of TM and the
molecular mechanisms involved in generation of TM in
hpg.ARKO mice are likely to be similar to those in the
human. This mouse model can be used, therefore, to
study the generation and characteristics of TM including
identification of changes in gene expression and protein
secretion associated with formation of TM. In addition,
the hpg.ARKO mouse now provides a chance to trace the
origins and physical development of testicular microliths.
In humans TM is normally diagnosed ultrasonically by
the presence of multiple 13 mm echogenic foci which are
clearly far larger than the structures observed microscopi-
cally in this study. This is likely to be a reflection of the dif-
ferences in testis size and tubule diameter between human
and hpg.ARKO mouse testes and the morphology of the
microliths appears very similar between mouse and
human [15]. Nevertheless, it should be noted that the cri-
teria used to define TM in this study is microscopic, rather
than ultrasonic, and direct extrapolation to the human
condition must be made with caution. Clearly, in this
respect, it will be of interest to determine whether there is
any development of TGCT in hpg.ARKO mice as they age
beyond early adulthood.
The origin of testicular microliths is uncertain. Most stud-
ies favour a tubular origin with accumulation of debris
from degenerating cells being followed by secretion of
glycoproteins and subsequent calcification [18,19]. Oth-
ers suggest that microliths originate outside the tubule
and then either move into the tubule or become engulfed
by the tubule folding around it [15,20]. Developmental
studies of TM in the hpg.ARKO mouse should provide a
clear answer to the origin of microliths. It may be of inter-
est, however, that microliths are much more prevalent in
hpg.ARKO mice than in hpg.SCARKO mice since one of
the differences between these two animal models lies in
the presence of ARs in the extratubular space.
It is unlikely that microliths form consistently in the
hpg.ARKO mouse simply because there is abundant
degeneration of the germ cells. This may be a contributory
factor but there is marked degeneration of germ cells in
hpg, SCARKO and ARKO mice and only in hpg mice did we
see any evidence of occasional microliths in some ani-
mals. Similarly, cryptorchidism may be a contributory fac-
tor to microlith formation in hpg.ARKO mice but is
unlikely to be the principal cause as hpg and ARKO mice
Microliths in hpg and hpg.ARKO mice Figure 1
Microliths in hpg and hpg.ARKO mice. Tissue sections 
showing microliths in hpg.ARKO (A, B, C) and hpg (D) mice. 
In A) the microliths are identified by yellow arrows. In C) and 
D) the white arrows identify Sertoli cells apposed to the 
microliths. The line represents 100 μm in A) and 10 μm in 
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are cryptorchid and no evidence of microliths was seen in
normal animals rendered cryptorchid by surgical means.
In hpg.ARKO mice the epididymides fail to form which
means that there will be a block to the flow of fluid
through the seminiferous tubules. This may also be a con-
tributory factor to the formation of microliths in the
hpg.ARKO mouse but is unlikely to be the major cause
since there is a similar failure of epididymal development
in ARKO mice. Removal of gonadotrophin stimulation is
clearly a contributory factor to microlith formation as, in
itself, it appears to be sufficient to induce formation of
occasional microliths in the hpg mouse. Overall, there-
fore, it may be a combination of factors (degenerating
cells, cryptorchidism, lack of tubular fluid flow), linked to
loss of gonadotrophin- and androgen-stimulation, that
leads to consistent TM development in the hpg.ARKO
mouse.
Conclusion
We have shown that the hpg.ARKO mouse consistently
develops TM. This provides a new and valuable model for
studying the cellular and molecular mechanisms involved
in TM development.
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